Evaluation of acoustic membrane microparticle (AMMP) technology for a sensitive ligand binding assay to support pharmacokinetic determinations of a biotherapeutic

Abstract

Achieving the required sensitivity can be a challenge in the development of ligand binding assays for pharmacokinetic (PK) determinations of biotherapeutics. To address this need, BioScale's Acoustic Membrane Microparticle (AMMP) technology was evaluated for the quantification of a PEGylated domain antibody (dAb) biotherapeutic. Previous uses of this technology had shown utility in biomarker and process development applications and this is the first application, to our knowledge, for PK determinations. In this evaluation, AMMP was capable of delivering a sensitivity of 0.750 ng/mL, which surpasses the sensitivity requirements for the majority of assays to support PK determinations. This evaluation demonstrates that this emerging technology has the ability to produce the required sensitivity, reproducibility, and selectivity needed to meet the industry's standards for PK analysis.

Fig. 1

a Schematic representation of how the AMMP platform works. b Sandwich format: drug detection with polyclonal anti-drug antibody immobilized on the magnetic bead and the same polyclonal anti-drug antibody, fluorescein labeled, for detection of the complex on the sensor. Competition format: drug detection with the drug immobilized on the magnetic bead and the polyclonal rabbit anti-drug antibody, fluorescein labeled, competing for detection of the complex on the sensor

Fig. 2

Competition format standard curves